Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Helicase with zinc finger domain (HELZ) is a member of the superfamily 1 (SF1) RNA helicases that contains an N-terminal CCCH-type zinc finger motif and operates primarily in regulation of RNA metabolism[2]. HELZ is implicated in mRNA stability, translational repression, mRNA decay, and deadenylation, notably via direct binding to the CCR4–NOT deadenylase complex[2]. The C-terminal region of HELZ binds the NOT module within CCR4–NOT and triggers deadenylation and decapping-dependent decay of associated mRNAs[2]. HELZ can also stimulate translation and interacts with polyadenylate-binding protein 1 (PABPC1), influencing the fate of polyadenylated RNAs. HELZ is widely expressed, including during embryonic development, and regulates the abundance of transcripts involved in neurogenesis and nervous system development[2]. There is evidence for its down-regulation in various cancers, but it is not currently characterized as a direct therapeutic target, and no drugs are known to interact with this protein. Though its mechanistic functions overlap with those of canonical mRNA repressors, it is not classified as a traditional receptor or classic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Helicase with zinc finger domain (HELZ).